UnitedHealth’s i3 Unit Tapped By FDA To Provide Postmarketing Surveillance
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is close to reaching additional deals with manufacturers for use of its i3 Aperio postmarketing surveillance drug registry.
You may also be interested in...
Lunesta, Crestor, Sanctura Among New Products In UnitedHealth Registry
UnitedHealth subsidiary Ingenix announces 14 new products to be included in the Aperio postmarketing surveillance registry. By year-end, the company expects the registry will include all the recent NMEs used by more than 1,000 UnitedHealth patients.
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.
User Fee Deal For Ad Review Funds Stems From PhRMA DTC Principles
A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles